Author:
Luo Lan,Jiao Yang,Li Yan,Yang Ping,Gao Jinjie,Huang Sai,Huang Wenyang,Wang Jijun,Dong Fei,Ke Xiaoyan,Zou Dehui,Gao Chunji,Jing Hongmei
Funder
the National Clinical Key Specialty Construction Program, P. R. China (2023).
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Bassan R, Maino E, Cortelazzo S (2016) Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol 96:447–460. https://doi.org/10.1111/ejh.12722
2. Hoelzer D, Gökbuget N (2009) T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma 9(Suppl 3):S214–221. https://doi.org/10.3816/CLM.2009.s.015
3. Jain P, Kantarjian H, Ravandi F et al (2014) The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28:973–975. https://doi.org/10.1038/leu.2013.312
4. Reiter A, Schrappe M, Ludwig WD et al (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95:416–421
5. Levine JE, Harris RE, Loberiza FR et al (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476–2482. https://doi.org/10.1182/blood-2002-05-1483